Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Fair Brett
 2. Date of Event Requiring Statement (Month/Day/Year)
04/13/2018		 3. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ACRS]
(Last)
(First)
(Middle)
C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Commercial Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

WAYNE, PA 19087		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3,141
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)   (1) 12/17/2025 Common Stock 35,000 $ 28.68 D  
Employee Stock Option (right to buy)   (1) 12/14/2026 Common Stock 48,600 $ 28.92 D  
Employee Stock Option (right to buy)   (1) 01/31/2028 Common Stock 54,000 $ 22.09 D  
Restricted Stock Units   (2)   (2) Common Stock 3,500 $ (3) D  
Restricted Stock Units   (4)   (4) Common Stock 7,088 $ (3) D  
Restricted Stock Units   (5)   (5) Common Stock 15,500 $ (3) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Fair Brett
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE, PA 19087		       Chief Commercial Officer  

Signatures

/s/ Brian F. Leaf, attorney-in-fact 04/17/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
(2) The shares underlying these restricted stock units vest in two equal annual installments on December 18, 2018 and December 18, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
(3) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
(4) 3,488 of the shares underlying these restricted stock units will vest in three equal annual installments beginning on December 15, 2018 and the other 4,500 of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
(5) The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
 
Remarks:
Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.